In the first in-depth interview with the press since the FDA’s letter, 23andMe spokesperson Catherine Afarian told VentureBeat that the company’s decision will shape the entire genetics industry, which she believes is the “future of medicine.”
At 23andMe, genetic analysis is out, but ancestry info and raw data are still very much in.
Guest Post Stanford bioethics professor Hank Greely provides in-depth analysis on the 23andMe case, and its broader relevance to the genetics industry.
Guest Post Even a product with such great potential should have to support its claims with valid evidence.
It’s clear that 23andMe believes its actions will have implications for other startups in the genetic testing field.
Editor’s Pick In the event that this divisive case reaches the California courts, it will have far reaching implications for the entire health care industry.
Genealogy company 23andMe has received a public warning letter from the Food and Drug Administration (FDA) for marketing its genetic testing kit without proper clearance and approval.
Editor’s Pick Thousands of people are sharing genetic information on social media sites. Our in-depth report delves into the privacy risks.
Guest Post Can you use 23andMe without giving the company all of your personal info? Definitely.
Food, food, and more food in today’s Funding Daily. Tis the season to be hungry for food startups.
Here’s an API launch that won’t leave you yawning: 23andme is opening up its treasure trove of genetics data to third-party developers.
You may not think music is in your genes, but a new lab from 23andMe may just prove you wrong.
Guest Post The cost of sequencing the human genome continues to fall, reaching a low of $1,000 this year due to a new microchip and machine designed by genetics company Life Technologies Corp. And unleashed by those lower costs, a small cadre of entrepreneurs in Silicon Valley is exploring ways to harness this data to enable us to live longer and healthier lives.